Covaris is a developer and manufacturer of instruments, consumables and reagents for sample preparation used in genomic sequencing and other advanced life sciences analyses. Based in Woburn, MA, the Company produces automated, high-throughput offerings that use proprietary acoustic technology to enable tissue extraction from preserved biopsy samples, DNA fragmentation, cell lysis, accelerated binding partner mixing, bead resuspension, and compound formulation. Covaris products are suitable across a variety of sample types and customers. Its instruments have applications across genomic sequencing, proteomics and multi-omics, and help accelerate the pace of research and life science innovation.
New Mountain identified Covaris as a result of the firm’s long-standing sector “deep dive” in Life Sciences Products, which has led to our previous investments in Avantor, Ikaria, Gelest, Aceto, ILC Dover, and Ascensus. New Mountain developed a strong relationship with the Company’s founders and management team, which led Covaris to choose New Mountain as its preferred strategic partner. As part of the transaction, the founders of Covaris reinvested alongside New Mountain.